Rates and predictors of starting a triptan

Results from the American Migraine Prevalence and Prevention Study

Marcelo E. Bigal, Dawn C. Buse, Ya Ting Chen, Wendy Golden, Daniel Serrano, Min Kyung Chu, Richard B. Lipton

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background. - Although diagnostic rates for migraine have increased over the past 5 years, the proportion of migraine sufferers using triptans has remained essentially stable. Objectives. - To assess the rate of onset of new triptan prescriptions among persons with migraine and the predictors of initiating therapy. Methods. - The American Migraine Prevalence and Prevention Study is a longitudinal study conducted in a representative sample of headache sufferers in the US population. Episodic migraineurs not using triptans in 2005 who continued to have migraine and provided treatment data in 2006 (n = 6865) were included. We assessed predictors of triptan use in univariate and multivariate analyses, including 3 nested models. In Model 1, we adjusted for demographic variables. Model 2 added headache-related disability and cutaneous allodynia. Model 3 added depression and use of preventive headache medications. Results. - Among individuals not using triptans in 2005, triptan use in 2006 occurred in 4.9% of the sample. In unadjusted analyses, gender and race were not associated with use of triptan. Use was lower in those aged 60 years or more vs those 18-29 (odds ratio [OR] = 0.4, 95% confidence interval [CI] = 0.2-0.7, P =.001). Taking individuals with no disability as the reference, mild (OR = 1.44, 95% CI = 1.03-2.01, P =.03), moderate (OR = 1.54, 95% CI = 1.1-2.2, P =.01) and severe disability (OR = 2.19, 95% CI = 1.55-3.09, P <.0001) predicted triptan use. In the adjusted models, age, income, insurance, disability and preventive medication use were associated with triptan use. Gender, race, education and depression were not. Conclusions. - New use of triptans is low in the population. Because adequacy of care was not assessed, future studies should focus on investigating whether this low rate of triptan start is proper or if it reflects an unmet treatment need.

Original languageEnglish (US)
Pages (from-to)1440-1448
Number of pages9
JournalHeadache
Volume50
Issue number9
DOIs
StatePublished - Oct 2010

Fingerprint

Tryptamines
Migraine Disorders
Cross-Sectional Studies
Odds Ratio
Confidence Intervals
Headache
Disability Insurance
Depression
Hyperalgesia
Population
Prescriptions
Longitudinal Studies
Therapeutics
Multivariate Analysis

Keywords

  • adequacy of care
  • migraine treatment
  • triptan

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Rates and predictors of starting a triptan : Results from the American Migraine Prevalence and Prevention Study. / Bigal, Marcelo E.; Buse, Dawn C.; Chen, Ya Ting; Golden, Wendy; Serrano, Daniel; Chu, Min Kyung; Lipton, Richard B.

In: Headache, Vol. 50, No. 9, 10.2010, p. 1440-1448.

Research output: Contribution to journalArticle

Bigal, Marcelo E. ; Buse, Dawn C. ; Chen, Ya Ting ; Golden, Wendy ; Serrano, Daniel ; Chu, Min Kyung ; Lipton, Richard B. / Rates and predictors of starting a triptan : Results from the American Migraine Prevalence and Prevention Study. In: Headache. 2010 ; Vol. 50, No. 9. pp. 1440-1448.
@article{84b42586509d4d6bb82ef88eb687f3e2,
title = "Rates and predictors of starting a triptan: Results from the American Migraine Prevalence and Prevention Study",
abstract = "Background. - Although diagnostic rates for migraine have increased over the past 5 years, the proportion of migraine sufferers using triptans has remained essentially stable. Objectives. - To assess the rate of onset of new triptan prescriptions among persons with migraine and the predictors of initiating therapy. Methods. - The American Migraine Prevalence and Prevention Study is a longitudinal study conducted in a representative sample of headache sufferers in the US population. Episodic migraineurs not using triptans in 2005 who continued to have migraine and provided treatment data in 2006 (n = 6865) were included. We assessed predictors of triptan use in univariate and multivariate analyses, including 3 nested models. In Model 1, we adjusted for demographic variables. Model 2 added headache-related disability and cutaneous allodynia. Model 3 added depression and use of preventive headache medications. Results. - Among individuals not using triptans in 2005, triptan use in 2006 occurred in 4.9{\%} of the sample. In unadjusted analyses, gender and race were not associated with use of triptan. Use was lower in those aged 60 years or more vs those 18-29 (odds ratio [OR] = 0.4, 95{\%} confidence interval [CI] = 0.2-0.7, P =.001). Taking individuals with no disability as the reference, mild (OR = 1.44, 95{\%} CI = 1.03-2.01, P =.03), moderate (OR = 1.54, 95{\%} CI = 1.1-2.2, P =.01) and severe disability (OR = 2.19, 95{\%} CI = 1.55-3.09, P <.0001) predicted triptan use. In the adjusted models, age, income, insurance, disability and preventive medication use were associated with triptan use. Gender, race, education and depression were not. Conclusions. - New use of triptans is low in the population. Because adequacy of care was not assessed, future studies should focus on investigating whether this low rate of triptan start is proper or if it reflects an unmet treatment need.",
keywords = "adequacy of care, migraine treatment, triptan",
author = "Bigal, {Marcelo E.} and Buse, {Dawn C.} and Chen, {Ya Ting} and Wendy Golden and Daniel Serrano and Chu, {Min Kyung} and Lipton, {Richard B.}",
year = "2010",
month = "10",
doi = "10.1111/j.1526-4610.2010.01703.x",
language = "English (US)",
volume = "50",
pages = "1440--1448",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Rates and predictors of starting a triptan

T2 - Results from the American Migraine Prevalence and Prevention Study

AU - Bigal, Marcelo E.

AU - Buse, Dawn C.

AU - Chen, Ya Ting

AU - Golden, Wendy

AU - Serrano, Daniel

AU - Chu, Min Kyung

AU - Lipton, Richard B.

PY - 2010/10

Y1 - 2010/10

N2 - Background. - Although diagnostic rates for migraine have increased over the past 5 years, the proportion of migraine sufferers using triptans has remained essentially stable. Objectives. - To assess the rate of onset of new triptan prescriptions among persons with migraine and the predictors of initiating therapy. Methods. - The American Migraine Prevalence and Prevention Study is a longitudinal study conducted in a representative sample of headache sufferers in the US population. Episodic migraineurs not using triptans in 2005 who continued to have migraine and provided treatment data in 2006 (n = 6865) were included. We assessed predictors of triptan use in univariate and multivariate analyses, including 3 nested models. In Model 1, we adjusted for demographic variables. Model 2 added headache-related disability and cutaneous allodynia. Model 3 added depression and use of preventive headache medications. Results. - Among individuals not using triptans in 2005, triptan use in 2006 occurred in 4.9% of the sample. In unadjusted analyses, gender and race were not associated with use of triptan. Use was lower in those aged 60 years or more vs those 18-29 (odds ratio [OR] = 0.4, 95% confidence interval [CI] = 0.2-0.7, P =.001). Taking individuals with no disability as the reference, mild (OR = 1.44, 95% CI = 1.03-2.01, P =.03), moderate (OR = 1.54, 95% CI = 1.1-2.2, P =.01) and severe disability (OR = 2.19, 95% CI = 1.55-3.09, P <.0001) predicted triptan use. In the adjusted models, age, income, insurance, disability and preventive medication use were associated with triptan use. Gender, race, education and depression were not. Conclusions. - New use of triptans is low in the population. Because adequacy of care was not assessed, future studies should focus on investigating whether this low rate of triptan start is proper or if it reflects an unmet treatment need.

AB - Background. - Although diagnostic rates for migraine have increased over the past 5 years, the proportion of migraine sufferers using triptans has remained essentially stable. Objectives. - To assess the rate of onset of new triptan prescriptions among persons with migraine and the predictors of initiating therapy. Methods. - The American Migraine Prevalence and Prevention Study is a longitudinal study conducted in a representative sample of headache sufferers in the US population. Episodic migraineurs not using triptans in 2005 who continued to have migraine and provided treatment data in 2006 (n = 6865) were included. We assessed predictors of triptan use in univariate and multivariate analyses, including 3 nested models. In Model 1, we adjusted for demographic variables. Model 2 added headache-related disability and cutaneous allodynia. Model 3 added depression and use of preventive headache medications. Results. - Among individuals not using triptans in 2005, triptan use in 2006 occurred in 4.9% of the sample. In unadjusted analyses, gender and race were not associated with use of triptan. Use was lower in those aged 60 years or more vs those 18-29 (odds ratio [OR] = 0.4, 95% confidence interval [CI] = 0.2-0.7, P =.001). Taking individuals with no disability as the reference, mild (OR = 1.44, 95% CI = 1.03-2.01, P =.03), moderate (OR = 1.54, 95% CI = 1.1-2.2, P =.01) and severe disability (OR = 2.19, 95% CI = 1.55-3.09, P <.0001) predicted triptan use. In the adjusted models, age, income, insurance, disability and preventive medication use were associated with triptan use. Gender, race, education and depression were not. Conclusions. - New use of triptans is low in the population. Because adequacy of care was not assessed, future studies should focus on investigating whether this low rate of triptan start is proper or if it reflects an unmet treatment need.

KW - adequacy of care

KW - migraine treatment

KW - triptan

UR - http://www.scopus.com/inward/record.url?scp=77957723606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957723606&partnerID=8YFLogxK

U2 - 10.1111/j.1526-4610.2010.01703.x

DO - 10.1111/j.1526-4610.2010.01703.x

M3 - Article

VL - 50

SP - 1440

EP - 1448

JO - Headache

JF - Headache

SN - 0017-8748

IS - 9

ER -